Navigation Links
GE Healthcare studies report results of [18F]Flutemetamol research

Chalfont St. Giles, UK, July 20, 2011 - Recent clinical research data reported that the investigational amyloid imaging agent [18F]Flutemetamol showed highly consistent image interpretation1 and showed comparable in vitro binding to the Pittsburgh Compound-B ([C-11]PiB)) investigational imaging agent3. Flutemetamol is a GE Healthcare Positron Emission Tomography (PET) investigational imaging agent currently in phase III development being studied for the detection of beta amyloid using PET brain scans.

The buildup of beta amyloid in the brain can lead to the degeneration of neurons and is one of several markers implicated in the development of AD. Currently, AD is typically confirmed by identifying the presence of tissue markers, including beta amyloid plaques, in post-mortem brain samples. Use of targeted imaging agents may help physicians detect amyloid deposition in live humans.

"These results should provide encouragement for patients and clinicians about the value of amyloid imaging in diagnosing AD," said Jonathan Allis, MI PET Segment Leader, GE Healthcare Medical Diagnostics. "Use of PET imaging scans to detect AD pathology may enable physicians to make a more accurate and earlier diagnosis of the disease."

Data highlights from three clinical abstracts to be featured at the 2011 Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) in Paris suggest that:

  • Flutemetamol reader training provided a highly consistent method for interpreting PET images. Readers blinded to clinical information demonstrated high inter- and intra-reader agreement rates when interpreting the brain distribution of Flutemetamol as normal and abnormal images.
  • Flutemetamol imaging was consistent with the understanding that normal pressure hydrocephalus (NPH), a progressive condition associated with dementia, gait abnormalities and urinary incontinence, represents a heterogeneous population with evidence of AD pathology.
  • 6-CN-Flutemetamol is comparable to 6-CN-Pittsburgh Compound-B (PiB) in its ability to bind to beta amyloid in vitro.

"At GE Healthcare, we are fully committed to developing products and tools that enable physicians to make confident medical decisions, allowing patients to get accurate diagnosis earlier in the process," said Pascale Witz, CEO, GE Healthcare Medical Diagnostics.

[18F]Flutemetamol is one part of a broad portfolio of diagnostic solutions that GE Healthcare is currently developing in the Alzheimer's field. The company is taking a comprehensive approach to understanding AD through its ongoing research to uncover the causes, risks and physical effects of the disease. GE Healthcare's global commitment to advance clinical knowledge and provide a variety of technologies to aid the fight in this epidemic may assist physicians in the acceleration of diagnosis and improvement of treatment decisions in all stages of the disease. The company already offers a range of imaging modalities used by physicians to assist in the detection of AD and dementia (CT, MRI, PET, SPECT) and has been a key contributor to the Alzheimer's Disease Neuroimaging Initiative since its inception. GE Healthcare also plays a key role in PredictAD, an EU-funded research project to develop solutions to enable earlier diagnosis of AD.


Contact: Aleisia Gibson
Edelman Public Relations

Related biology news :

1. TGen, Scottsdale Healthcare, Mayo Clinic study new drug to stimulate immune system of cancer victims
2. Phoenix conference highlights TGens and Scottsdale Healthcares contributions to molecular oncology
3. TGen Clinical Research Services at Scottsdale Healthcare and Mayo Clinic study new cancer drug
4. TGen-Scottsdale Healthcare researchers make breakthrough in lung cancer
5. GE Healthcare President & CEO, Mark Vachon, to Present at BioConference Live
6. GE Healthcare to evaluate and develop novel imaging technology
7. Scott & White Healthcare researcher finds success with new anti-cancer drug
8. Scott & White Healthcare researcher finds success with new anti-cancer drug
9. The Full Yield, Inc. Launches Breakthrough Collaboration to Put Food Back at the Heart of Healthcare
10. Inventor honored for tech improving access to clean water, healthcare, and business development in India
11. Lexicon to Present Clinical Data for Diabetes Drug Candidate, LX4211, at Two Major Healthcare Conferences
Post Your Comments:
(Date:9/30/2015)... PALM BEACH GARDENS, Fla. , Sept. 30, 2015 ... Circuit earlier this month issued another key ruling in ... Commission,s (ITC,s) determination that Korean fingerprint scanner company Suprema ... the Tariff Act of 1930, a trade provision that ... connection with import trade, by infringing two of Crossmatch,s ...
(Date:9/29/2015)... -- News facts: , ... , Minimized design shrinks PC footprint , ... embedded Fujitsu PalmSecure authentication enable enterprises to realize benefits ... that good things come in small packages, with the ... desktop and mobile portfolio. Featuring workplace design that favors ...
(Date:9/28/2015)... 2015 CLEAR, the leading biometric ... traveler service is coming to Austin-Bergstrom International ... a frictionless experience, serious speed and enhanced ... offers our travelers an expedited security screening ... Jim Smith , Executive Director, Austin-Bergstrom International ...
Breaking Biology News(10 mins):
(Date:10/13/2015)... ... October 13, 2015 , ... ... announced that it has received a Phase I Small Business Innovative Research (SBIR) ... Institute of General Medical Sciences (NIGMS), will fund the development of a technique ...
(Date:10/13/2015)... Oct. 13, 2015  According to Kalorama Information, ... reach $102 billion by the end of 2015. ... health industry, as it is estimated that approximately ... laboratory tests. In addition to diagnosing patients, clinical ... disease progression, monitor drug treatment and conditions, and ...
(Date:10/13/2015)... NC (PRWEB) , ... October 13, 2015 , ... ... intensity focused ultrasound (HIFU) technologies, announced today that it received de novo clearance ... in the U.S. for the ablation of prostate tissue. Sonablate® is the ...
(Date:10/12/2015)... , Oct. 12, 2015  Amgen (NASDAQ: AMGN ... from an exploratory sub-study of the previously reported romosozumab Phase ... an oral plenary session at the American Society for Bone ... Seattle . 2 --> ... sub-study data showed that, at month 12, the investigational bone-forming ...
Breaking Biology Technology: